BusinessManufacturing

Tesla Q3 Profits Slump Despite Revenue Growth as Costs Mount

Tesla reported a significant 37% drop in net income despite achieving its first revenue increase in three quarters. The electric vehicle maker faced pressure from lower vehicle prices and rising operational expenses linked to artificial intelligence projects.

Tesla’s Profitability Challenge

Tesla faced a challenging third quarter as increased costs significantly outweighed revenue growth, according to reports from CNBC’s Daily Open newsletter. Despite achieving a 12% year-over-year revenue increase—marking the company’s first revenue growth in three quarters—net income reportedly plunged 37% from the same period last year.

BusinessHealthcareInnovation

Takeda Forges $11.4 Billion Oncology Partnership with China’s Innovent Biologics

In a landmark move for the pharmaceutical industry, Japan’s Takeda Pharmaceutical has entered into a strategic collaboration with China’s Innovent Biologics. The partnership, valued at up to $11.4 billion, focuses on developing innovative cancer treatments through shared expertise and resources.

Major Pharmaceutical Alliance Forms

In a significant development for the global healthcare sector, Takeda Pharmaceutical Company has entered into a substantial collaboration with China’s Innovent Biologics Inc. to jointly develop cancer therapies, according to recent reports. This partnership represents one of the largest cross-border pharmaceutical deals in recent years and highlights the growing importance of Chinese biotech firms in the global drug development landscape.